- MESOBLAST LIMITED : 15 May 2013 - Mesoblast's Preclinical Trial Results of ...
- Mesoblast Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and ...
- MESOBLAST LIMITED : 15 May 2013 - Mesoblast's Preclinical Trial Results of ...
- MESOBLAST LIMITED : 17 April 2013 – Mesoblast Appoints Renowned ...
- MESOBLAST LIMITED : 12 April 2013 - Mesoblast Chief Executive Honoured at ...
- MESOBLAST LIMITED : 12 April 2013 - Mesoblast Chief Executive Honoured at ...
- MESOBLAST LIMITED : 12 April 2013 - Mesoblast Chief Executive Honoured at ...
- MESOBLAST LIMITED : 13 March 2013 - Mesoblast Completes A$170m Private ...
- MESOBLAST LIMITED : 13 March 2013 - Mesoblast Completes A$170m Private ...
- MESOBLAST LIMITED : 11 February 2013 - Mesoblast Reports Half-Year 2013 ...
- FDA Agree on Use of MSBs Singapore Manufacturing Facility
- Mesoblast Limited (ASX: MSB) (OTC ADR: MBLTY) Earnings and Development ...
- Mesoblast Limited (ASX: MSB) (USOTC: MBLTY) Key Mesenchymal Precursor ...
- Mesoblast, patents and China
- Mesoblast limited
- FDA Clears Phase 2 Clinical Trial for Rheumatoid Arthritis
- FDA Clears Phase 2 Clinical Trial for Rheumatoid Arthritis
- Positive Results in Phase 2 Lumbar Spinal Fusion Trial
- MESOBLAST LIMITED : 13 December 2012 - Blood Cell Expansion Trial in New ...
- Mesoblast Corporate Overview - CEO Message to AGM
- MESOBLAST LIMITED : 20 November 2012 - Mesoblast Reaches Key ...
- MESOBLAST LIMITED : 19 November 2012 – Market Update
- Mesoblast Ltd Completes Acquisition Of Angioblast Systems Inc; Announces Shares Placement; Cephalon, Inc. Acquires Shareholding In Mesoblast Ltd
- Nobel Winner's Stem Cells to Be Tested in Eye Malady in 2013
- Analyst quick to defend honour of biopharma Mesoblast
- Australian Stock Market Report – Midday 9/25/2012
- A biotech bonanza may be just hype
- Rexahn Reports Positive Phase 2 Data for Archexin; Dynavax Announces FDA ...
- World Leader in Regenerative Medicine to Be Among Companies Attending ...
- Cellmid appoints Graeme Kaufman as non executive director
- Cellmid appoints Graeme Kaufman as non executive director
- Mesoblast stem cell R&D spend triples
- Chandler Macleod posts 45pc proft rise
- Chandler Macleod posts 45pc proft rise
- Bankable asset CBA posts record profit but warns of cloudy outlook
- Australia's two-decade expansion at risk, McKinsey report warns
- Companies struggling with Facebook and Twitter backlash
- Health is a very good asset
- Commercial property values slump to lows
- Market big wigs face the music
- Country Road to take over Witchery
- The Short Report
- Midday: Aus shares 0.3% higher
- Midday: ASX lifts from lows on CPI
- RegMed sector is starting to heat up on the Hot Tin Roof
- Rheumatoid Arthritis New Major Clinical Target After Mesoblast Obtains ...
- Biotechs undo gains from last quarter
- Mesoblast Interview: The Best Adult Stem Cell Technology In The World?
- Australian shares flat ahead of BoE, ECB
- Australian shares flat ahead of BoE, ECB
- Outlook: ASX set to follow positive leads
- QRxPharma product approval hits hurdle
- Property performance this financial year
- Market Wrap: ASX up 0.7%
- Market Wrap: Aus shares close 0.4% lower
- The Short Report
- Midday: Aus shares fall on global fears
- The investor's guide to surviving a sharemarket crash
- The investor's guide to surviving a sharemarket crash
- The investor's guide to surviving a sharemarket crash
- NBN Co chooses Leighton, Service Stream
- Market Wrap: Aus shares close 1.1% lower
- 3 ASX stocks that beat the market yesterday
- Mesoblast insists Teva partnership is strong
- Market Wrap: ASX rises 0.4%
- ASX Market Wrap: ASX finishes the week on a positive note
- BHP lowers sights as commodity price forecasts dip in medium term
- The Short Report
- Mesoblast Provides Corporate Strategy For Product Development To Treat ...
- Crawling through the tape to see what's working … not much!
- New Teva Representative Joins Mesoblast Board of Directors
- FDA Petition
- Teva Representative Joins Mesoblast's Board of Directors
- New Teva Representative Joins Mesoblast Board of Directors
- Mesoblast limited : Msb asx new director - 10 may 2012
- Australian Stock Market Report – Midday 5/2/2012
- Australian Stock Market Report – Midday 5/2/2012
- Three questions to answer before the market plunges
- Mesoblast hits 50% enrolment for back pain trial
- Australian Stock Market Report – Afternoon 4/19/2012
- Australian Stock Market Report – Midday 4/18/2012
- Australian Stock Market Report – Midday 4/18/2012
- Intervertebral Disc Repair Phase 2 Trial Update
- ASX healthcare companies rebound in 2012: Acrux, ResMed, Mesoblast
- Athersys (ATHX) Secures New GvHD Patent for MultiStem
- iSonea expands board expertise with new director appointments
- iSonea expands board expertise with new director appointments
- iSonea expands board expertise with new director appointments
- Mesoblast Update to Credit Suisse Asia Investment Conference
- FDA Clears Mesoblast Ltd For Advanced Trials Of Back Pain Treatment-DJ
- Market Wrap: ASX posts third weekly loss
- Half Year Results - Mesoblast Posts Strong Cash Balance
- IG Markets - Afternoon thoughts 27/2/12
- Arizona Pain Specialists conducts pain study
- Mesoblast Ltd Enters Into Strategic Alliance With Lonza Group Ltd
- Mesoblast Ltd Receives Clearance To Begin First European Trial Of Allogeneic Or 'Off-The-Shelf' Stem Cell Treatment For Heart Attacks
- Mesoblast Ltd Not To Pay FY 2011 Final Dividend
- First Minimally-Invasive Procedure Performed In Mesoblast Ltd's Phase 2 Stem Cell Trial For Lumbar Disc Repair
- Mesoblast Ltd Receives FDA Clearance For Phase 3 Bone Marrow Transplant Trial
- Mesoblast Ltd Receives FDA Approval For Bone Marrow Transplant Trial-DJ
- Positive Outcome from FDA Meeting
- Mesoblast posts successful results from diabetes stem cell trial
- Mesoblast Cleared to Begin First Phase 2 Clinical Trial for Eye Diseases
- Mesoblast receives clearance
- Phase 2 Stem Cell Trial for Lumbar Disc Repair
- Presentation in Special Session of American Heart Association Annual Conference
- Mesoblast Receives FDA Clearance
- Mesoblast (ASX:MSB) Success in recent heart trials
- Key Patents Granted In United States Strengthen Commercial Rights And Broaden Clinical Indications
- Teva buying Cephalon for $6.8 billion